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PENILAIAN PERSEPSI DAN KEBERKESANAN INTERVENSI KALENDAR 
BLISTER PEK TERHADAP PEMATUHAN UBAT DAN HASIL KLINIKAL 
DALAM KALANGAN PESAKIT HIPERTENSI DI HOSPITAL KULIM, 
MALAYSIA. METODOLOGI CAMPURAN 
 
ABSTRAK 
Tujuan kajian ini dijalankan adalah untuk meneroka persepsi terhadap 
pembungkusan ubat dan kalendar blister pek (CBP), menilai keberkesanan CBP 
terhadap pematuhan ubat, hasil klinikal (tekanan darah) serta kos rawatan yang 
berkaitan dengan intervensi tersebut dalam kalangan pesakit hipertensi di Hospital 
Kulim, Malaysia. Kajian ini melibatkan metodologi campuran, iaitu kaedah kualitatif 
dan kuantitatif. Dalam fasa I, dua sesi perbincangan kumpulan berfokus telah 
dijalankan dalam kalangan 16 pesakit hipertensi untuk mengumpul maklumat 
mengenai persepsi pesakit terhadap pembungkusan ubat dan CBP dalam rawatan 
penyakit hipertensi. Maklumat yang dikumpulkan diterjemahkan secara verbatim dan 
dianalisis dengan menggunakan kaedah analisis tematik untuk mengenal pasti tema-
tema baru. Fasa II dalam kajian ini ialah percubaan klinikal terkawal rawak dengan 
hasil kajian fasa ini adalah pematuhan ubat, bacaan tekanaan darah dan kos rawatan 
untuk pesakit dalam kajian ini. Kos rawatan ini termasuk kos ubat-ubatan, lawatan 
klinik, kemasukan wad, prosedur perubatan dan ujian diagnostik. Kesahihan 
konvergen dan kumpulan yang diketahui telah dijalankan untuk mengesahkan alat 
pengukuran kepatuhan yang diguna dalam kajian ini. Analisis tematik menghasilkan 
tiga tema utama iaitu pengetahuan dan kebiasaan terhadap nama ubat dan 
pembungkusan ubat; persepsi mengenai pembungkusan dan label ubat-ubatan; 
pengetahuan dan pandangan terhadap CBP. Setiap tema utama tersebut mengandungi 
xv 
  
dua atau tiga subtema. Pesakit hipertensi yang menyertai perbincangan kumpulan 
berfokus ini bersetuju bahawa CBP adalah suatu intervensi yang hebat untuk 
meningkatkan kesedaran pesakit tentang kekerapan penggunaan ubat, meningkatkan 
pematuhan ubat dan mengurangkan kesilapan penggunaan ubat-ubatan. Dalam 
percubaan klinikal terkawal rawak, seramai 83 pesakit hipertensi, yang sedang 
menerima rawatan untuk hipertensi dengan menggunakan ubat amlodipine, telah 
direkrut dan dibahagikan secara rawak ke dalam kumpulan intervensi (N=41) dan 
kumpulan kawalan (N=42). Pesakit-pesakit ini dijadualkan untuk melawat farmasi 
yang menjalani kajian ini setiap 28 hari, selama tujuh bulan dalam tempoh pengajian, 
untuk mengisi preskripsi mereka. Kajian ini mendapati bahawa pesakit dalam 
kumpulan intervensi mempunyai skor pematuhan ubat yang lebih baik pada akhir 
kajian ini berbanding dengan kumpulan kawalan, dengan menggunakan skala 
kepatuhan ubat Morisky (7.414 berbanding 6.796, p<0.05); nisbah pemilikan ubat 
(0.991 berbanding 0.979, p<0.05); peratusan pengisian preskripsi yang tepat pada 
masanya (0.992 berbanding 0.929, p<0.05). Selain itu, kumpulan intervensi 
menujukkan bacaan tekanan darah yang lebih rendah berbanding dengan kumpulan 
kawalan (123.590/78.057mmHg berbanding 129.728/81.360mmHg, p<0.05). Dari 
perspektif hospital, purata kos rawatan tahunan bagi pesakit dalam kumpulan 
intervensi adalah RM 2178.66 (95% CI 1786.39-2570.94) berbanding dengan RM 
2693.09 (95% CI 1903.23-3482.95) dalam kumpulan kawalan. Di samping itu, kajian 
ini mendapati bahawa skala kepatuhan ubat Morisky tidak berkiat rapat dengan nisbah 
pemilikan ubat dan peratusan pengisian preskripsi yang tepat pada masanya (p>0.05). 
Unutk kesahihan kumpulan yang diketahui, usia pesakit dan tekanan darah berkiat 
rapat dengan skala kepatuhan ubat Morisky (p<0.05). Manakala, pesakit yang telah 
didiagnosis dengan hipertensi kurang dari lima tahun mempunyai nisbah pemilikan 
xvi 
  
ubat yang lebih tinggi berbanding dengan persakit yang telah didiagnosis hipertensi 
lebih daripada lima tahun (p<0.05). Kesimpulannya, kajian ini telah memberi 
gambaran tentang pendapat, persepsi dan pengalaman pesakit hipertensi terhadap 
pembungkusan ubat dan ubat-ubatan CBP. Selain itu, kajian ini juga membuktikan 
bahawa CBP mempunyai kesan positif terhadap pematahuan ubat, bacaan tekanan 
darah dan mempunyai potensi untuk penjimat kos rawatan yang agak memuaskan 





















EVALUATION OF THE PERCEPTION AND EFFECTIVENESS OF 
CALENDAR BLISTER PACK INTERVENTION ON MEDICATION 
ADHERENCE AND CLINICAL OUTCOME AMONG HYPERTENSIVE 




This study aimed to explore patients’ perception on medication packaging and 
calendar blister pack (CBP), to assess the effectiveness of CBP intervention towards 
medication adherence, clinical outcome (blood pressure) as well as the cost associated 
with the said intervention among hypertension patients in Kulim Hospital, Malaysia. 
A mixed methodology approach which involved both qualitative and quantitative 
methodology were implemented in this study. In phase I study, two focus group 
discussions were conducted among 16 hypertensive patients to collect data on patient’s 
perception towards medication packaging and CBP medications in managing 
hypertension. Collected data were transcribed verbatim and analysed by thematic 
analysis to identify the emerging themes. Phase II in this study was designed as a 
randomized controlled trial with the study outcomes were medication adherence, blood 
pressure level and treatment costs which included costs for prescribed medications, 
clinic visit, hospitalization, medical procedure and diagnostic test. Convergent and 
known group validity were performed to validate the adherence measurement tools 
used in this study. The thematic analysis yield three major themes which were 
knowledge and familiarity with the medicine names and their packaging; perception 
about the packaging and labelling of medicines; the knowledge and views of CBP. 
Each of this theme was further divided into two or three subthemes. Patients agreed 
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that CBP is a great intervention to increase patient awareness on regular medicines use, 
enhance medication adherence and reduce medication errors. In randomized control 
trial, a total of 83 hypertensive patients who are currently on amlodipine treatment 
were recruited and randomly assigned into intervention (N= 41) and control group (N= 
42). These patients were scheduled to visit the study pharmacy to refill their 
prescription every 28 days for seven months study period. This study found that 
patients in the intervention group have better medication adherence score at the end of 
this study compared to the control group as measured by Morisky medication 
adherence scale (7.414 versus 6.796, p<0.05); medication possession ratio (0.991 
versus 0.979, p<0.05) and percentage of on-time refill (0.992 versus 0.929, p<0.001). 
Besides, intervention group demonstrated significant lower blood pressure level than 
control group (123.590/78.057mmHg versus 129.728/81.360mmHg, p<0.05). From 
the provider perspective, the average annual treatment cost per patient in the 
intervention group was RM 2178.66 (95% CI = 1786.39-2570.94) compared to 
RM2693.09 (95% CI 1903.23-3482.95) in the control group. Besides, Morisky 
medication adherence scale was no significantly associated with medication 
possession ratio and percentage of on time refill in this study (p>0.05). For known 
group validity, patient age and blood pressure were significantly associated with 
Morisky medication adherence scale (p<0.05). While, for patients who have been 
diagnosed with hypertension for less than five years have higher medication 
possession ratio compare to patient who have been diagnosed for more than five years 
(p<0.05). In conclusion, this study has provided an insight into the opinion and 
perception of hypertensive patients towards medication packaging and CBP 
medications. Besides, the study findings provided evidence that CBP has a positive 
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impacts on medication adherence, blood pressure outcome and has the potential for 




CHAPTER 1 GENERAL INTRODUCTION 
1.1 Background  
Calendar blister pack (CBP) medication is an innovative unit-of-use (generally one 
month) packaging in which each pill’s blister is incorporate with a simple daily 
labelling such as times (morning, afternoon, evening), day of week or date of the 
month (Zedler et al., 2011b). Various designs of CBP have been developed, however 
the basic features for the CBP are the pill in packing can easier be pushed out through 
the blister without any effort or spilling. The calendar feature on the packaging enable 
the patients to know the number of pills left and how long before the patient need to 
refill their prescription (Huff, 2009).  
 
The first CBP medication was issued in 1963 for oral contraceptive Ortho-Novum with 
the intention to assist woman in adhering with their medications and this packaging 
gained good feedback from the user in improving their medication adherence (Gossel, 
1999). Prior to CBP, most of the interventions (as education, counselling, reminder 
calls and risk communication) to improve patient adherence require active 
involvement of healthcare resources as they are generally complex, labour intensive 
and costly. Whereas, CBP is a simple and passive intervention which could enhance 
patient adherence at lower cost compared to those complex and labour intensive 
intervention.  
 
The purpose of labelling the blister with calendar feature is to encourage the patients 
to follow the prescribed dosing schedule. Besides, it can provide a visual record to the 
patient on when is their last took of the medicines (Osterberg & Blaschke, 2005, 
Haynes et al., 2008). In addition, medications are clearly arranged in correct sequence 
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and interval which allow the patients to self-monitor the medication consumption, 
resulting in improvement of medication adherence and overall health outcome 
(Padigus, 2014). With the use of CBP, each pill stays and well protected in the blister 
pack until it is ready for consumption. Thus, the stability, efficacy and safeness of the 
medication are well protected by the blister pack. 
 
In general, CBP medications are commonly used for oral contraceptives, 
corticosteroids, antibiotics and female hormone replacement therapy (Osterberg & 
Blaschke, 2005, Schneider, Murphy & Pedersen, 2008). Until lately, more medications 
are packed in CBP such as antiretroviral, antituberculosis, and psychiatric medication 
in order to enhance patient adherence (Finch et al., 2003, Abraham et al., 2016, Ng & 
Caires, 2016). However, CBP is still not commonly used for long-term medication to 
treat chronic diseases or other classes of daily dosed medications such as hypertension. 
 
Poor medication adherence is a major problem in chronic diseases and studies reported 
that patient with chronic diseases only consume approximately 50% their medications 
prescribed by the healthcare professional (Sabaté, 2003, Brown & Bussell, 2011, 
Mathes et al., 2012). In addition, the total healthcare cost associated with poor 
medication adherence are approximately USD 106 billion per year in United States. 
Hence, medication adherence is one of the most important factor for managing chronic 
diseases. However, patient with chronic diseases usually required to consume several 
medications, as a result patient had difficulties to adhere to their medications. This 
thesis is to investigate whether the CBP intervention could improve medication 
adherence, clinical outcomes as well as the healthcare cost among hypertensive 




Hypertension is a medical condition where the force of the blood is consistently 
pushing against the artery wall at a high pressure and eventually may cause serious 
health problems. Hypertension is a chronic disease which can be controlled through 
healthy lifestyle and diet, but  cannot be cured by medication or prevented by vaccines 
(World Health Organization, 2013a, MedicineNet, 2016). It require life-time treatment 
plan to control this disease from progression (Goldstein, 2017).  
 
Hypertension is a silent killer where people with high blood pressure basically do not 
suffer from any specific physical symptoms or illness on them. Hence, hypertension is 
usually detected only by regular check-up on the blood pressure reading. Ignoring 
hypertension may increase the risk of getting life-threatening health complications 
(Pierin et al., 2016). Reports showed that the higher the blood pressure level, the major 
organs in the body such as heart, brain and kidneys will be in higher risk of getting 
harmful consequences such as coronary artery disease, stroke, congestive heart failure, 
cognitive impairment and chronic renal disease (Chobanian et al., 2003, Whelton, He 
& Muntner, 2004, World Health Organization, 2013a).  
 
1.1.2 Guidelines for hypertension 
According to the recommendation by the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC), normal blood 
pressure for healthy adults aged 18 years and above is defined as <120 mmHg / 80 
mmHg. Whereas, prehypertension is defined as systolic blood pressure between 120 
to 139 mmHg or diastolic blood pressure as 80 to 89 mmHg. Normal adults are 
considered to be on stage 1 hypertension if the systolic blood pressure is between 140 
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to 159 mmHg or diastolic blood pressure between 90 to 99 mmHg. Besides, stage 2 
hypertension are those who with blood pressure ≥ 160 mmHg / 100 mmHg (Chobanian 
et al., 2003). In general, blood pressure ≥140 mmHg / 90 mmHg is consider 
hypertension, this guideline is accepted worldwide including World Health 
Organization, National Institute for Clinical Excellence, American College of 
Cardiology, American Heart Association and European Society of Hypertension 
(World Health Organization, 2005, National Institute for Health and Clinical 
Excellence, 2011, Mancia et al., 2013, Go et al., 2014, Weber et al., 2014). Whereas, 
for diabetes, chronic renal disease and certain cardiovascular diseases patients, their 
target blood pressure is slight lower, which is 130mmHg / 80mmHg (Chobanian et al., 
2003).  
 
In 2014, the 8th JNC report suggested to start pharmacological treatment on general 
population older than 60 years old with blood pressure ≥ 150 mmHg / 90 mmHg and 
the treatment goal is below 150mmHg / 90mmHg. The treatment goal for adults older 
than 60 years old is different from adults aged below 60 years old. Adults older than 
60 years old have a higher systolic blood pressure as their treatment goal (150 mmHg 
/ 90 mmHg) compared to the treatment goal for adults below 60 years old, (< 140 
mmHg / 90 mmHg). Besides, pharmacological treatment should be initiated for adults 
younger than 60 years old with diastolic blood pressure of ≥ 90 mmHg. The targeted 
goal is below 90 mmHg. Whereas, in the population above 18 years old with either 
diabetes or chronic kidney disease, drug treatment to lower the blood pressure should 
be initiated at ≥ 140 mmHg / 90 mmHg and treatment threshold at < 140mmHg / 




In summary, the normal blood pressure for adults younger than 60 years old is < 120 
mmHg / 80 mmHg (Chobanian, 2017). General population aged below 60 years old 
with a blood pressure of ≥140 mmHg / 90 mmHg is consider being hypertension and 
they are advised to start the pharmacological treatment according to JNC 8 guidelines. 
Besides, for adult age 60 years old and above, they are advised to initiate 
pharmacological treatment if their blood pressure is ≥ 150 mmHg / 90 mmHg 
(Chobanian et al., 2003, James et al., 2014).   
 
A new guideline for prevention, detection, evaluation and management of high blood 
pressure in adults was release by American College of Cardiology and American Heart 
Association on November 2017. Based on this guideline, adults were consider to be 
normal blood pressure with the blood pressure below 120/80 mmHg, and patient was 
considered to be elevated blood pressure if the systolic blood pressure was between 
120-129 mmHg and diastolic blood pressure was less than 80 mmHg. Patient was 
diagnosed with stage I hypertension if the systolic blood pressure between 130-139 
mmHg or diastolic blood pressure between 80-89 mmHg. Patient was on stage II 
hypertension if the systolic blood pressure was above 140 mmHg or diastolic blood 
pressure at least 90 mmHg. Hypertensive crisis occur if the patient systolic blood 
pressure over 180 mmHg and/or diastolic blood pressure over 120 mmHg, patient need 
prompt changes in their medication if there are no other indications of problems, or 





1.1.3 Prevalence of hypertension 
Hypertension have been identified as one of the risk factors for global disease burden 
and is the fourth contributor to premature death in developed countries such as United 
States (Lim et al., 2012, Forouzanfar et al., 2015). The prevalence of hypertension is 
increasing in both developed and developing countries. This increment might be due 
to the global economic development, urbanization as well as lifestyle changes in 
society (Yach et al., 2004, World Health Organization, 2011a).  
 
According to World Health Organization global status report on non-communicable 
diseases 2014, the global prevalence of hypertension, defined as ≥ 140 mmHg / 90 
mmHg, in adults aged 18 years old and above was around 22% (World Health 
Organization, 2014a). Among the World Health Organization regions, Africa has the 
highest prevalence of hypertension with 30% of the adults in Africa have high blood 
pressure. Whereas, the lowest prevalence was America. Only 18% of adults aged 18 
and above in the region of America suffer from hypertension and the prevalence of 
hypertension in South-East Asia was 24.75% (World Health Organization, 2015). The 
number of hypertension patient rose dramatically from 600 million in 1980 to 1 billion 
in 2008, and by 2025, it is expected to increase to 1.56 billion globally (Kearney et al., 
2005, World Health Organization, 2013a, World Health Organization, 2014a). This 
increment pattern was similar to the study done by Forouzanfar and colleagues, where 
they reported the projected number of adults aged 25 years and above with systolic 
blood pressure of ≥ 140 mmHg increased from 442 million in 1990 to 874 million in 




The prevalence of hypertension is reported to be high across different countries in Asia, 
ranging from 19% in Democratic People’s Republic of Korea to 42% in Myanmar. In 
addition, there is a dramatically increment in the rate of hypertension among the 
countries in this region, such as India and Indonesia. The hypertension rate in India is 
reported to be only 5% in 1960s, nearly 12% in 1990s, and recently report showed that 
the percentage of adults with hypertension in India have increased to more than 30% 
in 2008 (Gupta, al-Odat & Gupta, 1996, Gupta, 2004, World Health Organization, 
2011b). Next, the prevalence of hypertension in Indonesia rose from 8% in 1995 to 
32% in 2008 (Krishnan, Garg & Kahandaliyanage, 2013). Lastly, World Health 
Organization reported that one in every three Asian adults suffer from high blood 
pressure (World Health Organization, 2013b). 
 
In Malaysia, there was an upward trend in the percentage of adults aged 30 years and 
above who is hypertension. Studies showed that the prevalence of hypertension for 
adults above 30 years old was significantly increased from 32.9% in 1996, to 43.5% 
in 2011(Lim, Morad & Hypertension Study Group, 2004, Gurpreet et al., 2012). 
Besides, according to Malaysia National Health and Morbidity survey 2015, the 
prevalence of hypertension for Malaysian adults aged 18 years and above was 30.3%, 
which is estimated 6.1 million of the Malaysia citizen currently are suffering from 
hypertension and more than half of these patients are with undiagnosed hypertension 
(Ministry of Health-Institute for Public Health, 2015). As compared to neighbouring 
countries such as Indonesia (23.0%), Singapore (26.5%) and Thailand (20.5%), 
Malaysia (30.3%) had the highest hypertension rate among adults age 18 years and 
above (Kearney et al., 2005, Ministry of Health-Institute for Public Health, 2015). In 
general, men (30.8%) have a higher prevalence rate of hypertension compared to 
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female (29.7%) and 7 out of 10 elderly citizen above 60 years old suffered from high 
blood pressure (Ministry of Health-Institute for Public Health, 2015). Next, the 
prevalence of hypertension was significantly higher in rural areas (33.5%) compared 
to urban areas (29.3%) in Malaysia. The number of hypertensive patients in Malaysia 
population will continue to increase annually due to the progressive aging among the 
population unless comprehensive preventive intervention that focuses on improving 
awareness, treatment and control of hypertension is implemented among the general 
population (Abdul-Razak et al., 2016). 
 
1.1.4 Burden of hypertension 
Hypertension is a risk factor for cardiovascular disease such as coronary heart disease 
and it is the most important risk factor for stroke. Patient with hypertension has 4 times 
higher risk of getting stroke and caused approximately 50% of ischaemic stroke 
(Stroke Association, 2012, Arboix, 2015). Besides, patient with high blood pressure 
has 3.9 and 2.8 times higher risk in cerebral haemorrhage and aneurysmal 
subarachnoid haemorrhage respectively compared to those with normal blood pressure 
(van Gijn & Rinkel, 2001, Arboix, 2015).  
 
On the other hand, World Health Organization research in 2004 showed that 
hypertension is estimated to cause 7.5 million deaths, approximately 12.8% of the total 
global deaths. Besides, hypertension is accounted for 57 million disability adjusted life 
years (DALYs) or 3.7% of total DALYs in the 2014 (World Health Organization, 
2009). Globally, there is a rising trend in the number of death due to hypertension. In 
2015, the annual number of deaths solely due to systolic blood pressure ≥ 140 mmHg 
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is 7.8 million or 14.0% of total global death, and has accounted for 143 million DALYs 
or 5.5% of the total DALYs (Forouzanfar et al., 2017).  
 
In terms of economic impact, the annual average of treatment cost for hypertension 
from 2011 to 2012 in United States was USD 48.6 billion and from 2012 to 2013 is 
estimated to be USD 51.2 billion (Mozaffarian et al., 2015, Benjamin et al., 2017). 
This amount included the both direct and indirect cost of hypertension. The direct 
medical cost such as healthcare services, medication, hospitalization and home 
healthcare; and the indirect cost of lost productivity related to morbidity and mortality 
caused by hypertension (American Heart Association, 2005). Besides, the American 
Heart Association projected the treatment cost for hypertension would increase to USD 
200 billion in 2030 (Heidenreich et al., 2011, Benjamin et al., 2017). 
 
In Malaysia, there was a total of 37,600 hospitalization cases which were related to 
hypertension in 2005. The total cost of hospitalization is RM 110 million (Ong & 
Rozina, 2009). Besides, a total number of deaths due to complication of hypertension 
was increasing and it was about 52,000 cases in 2014. It was about 36% of the total 
death in Malaysia (World Health Organization, 2014b). The death rate due to 
hypertension and its complication in Malaysia (36%) is high as compared to the global 
statistics (12.8%) on the deaths caused by hypertension. In addition, the total 
healthcare expenditure had also increased from RM 8.30 billion in 1997 to RM 44.75 
billion  in 2013 (Ministry of Health Malaysia, 2015). The total healthcare expenditure 
would continue to increase due to the chronic diseases such as hypertension and 




1.1.5 Factors affecting blood pressure control 
The main reason to treat hypertensive patients is to normalize the blood pressure and 
to prevent the disease progression which may lead to the cardiovascular event. 
However, in reality to control the blood pressure at the normal level is a challenging 
process by both healthcare provider and patients. Among the 71 million people in 
United States with high blood pressure, 48.2% of these individual do not have their 
blood pressure in control, which defined as ≥ 140 mmHg / 90 mmHg. Besides, among 
these individual with uncontrolled blood pressure, estimated about 13 million people 
are unaware of their blood pressure condition as well as not taking any 
antihypertensive medications (Nwankwo et al., 2013). A similar prevalence was found 
in Malaysia, whereby local studies showed that 51.7% of the hypertensive patients had 
poor blood pressure control (Cheong et al., 2015, Teoh et al., 2017). Besides, only 
34.6% of the hypertensive patients in Malaysia know their blood pressure condition, 
and among these patients, only 32.4% were treated with antihypertensive medicines 
and among patients who treated with antihypertensive medicines, only 30.3% achieved 
the targeted blood pressure (Abdul-Razak et al., 2016).  
 
Various studies have been conducted to determine the factors that affect blood pressure 
level among the patients (see Xu et al., 2013, Mungati et al., 2014, Alsolami, Correa-
Velez & Hou, 2015, Nawata et al., 2017). These studies come into a conclusion that 
there are multiple factors that may affected the blood pressure level. These factors can 
be categorized as non-modifiable and modifiable factors. Non-modifiable factors such 
as patient age, gender and ethnicity are factors beyond an individual control to change 
or adjust it to prevent the disease. On the other hand, modifiable factors are factors that 
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can be changed or adjustable to prevent an individual from developing the disease, 
such as lifestyle factors and patient adherence (Ibekwe, 2015).  
 
1.1.5.1 Non-modifiable factors 
Personal factors such as age, gender and ethnicity or race are non-modifiable factors 
that may affect the blood pressure level. 
 
Previous studies showed that the prevalence of hypertension in elderly individual aged 
60 years and above is as high as 60% to 80% (Egan, Zhao & Axon, 2010, Lionakis et 
al., 2012, Seow et al., 2015). This might due to the progressive increase of the systolic 
blood pressure over the time for individual age from 30 to 80 years and above. While 
diastolic blood pressure increases only until the age of 50, then it will either decrease 
or becomes stable (Williams, Lindholm & Sever, 2009). Thus, there is 90% risk of 
developing systolic hypertension in a normal blood pressure individual after the age 
of 55 years (Chobanian et al., 2003). Besides, there is a linear relationship between 
high systolic blood pressure with cardiovascular event such as stroke among the 
elderly hypertensive patient (Borghi et al., 2003, Weitzman & Goldbourt, 2006, Brown, 
Giles & Greenlund, 2007). 
 
Global data demonstrated that there is a higher percentage of men having high blood 
pressure compared to women until the age of 45. Age between 45 to 64 years old, the 
prevalence of hypertension is almost similar in both men and women; however, after 
the age of 64, women have a higher percentage of hypertension compared to men (Go 
et al., 2013). This might due to the female sex hormones such as oestrogen and 
progesterone which serve as the guardian for the blood pressure and heart. During the 
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menopause which usually happens in women around 45-60 years old, women start to 
loss their female sex hormones in their body; this might cause a rapid increase of blood 
pressure over the time. As a result, women have higher blood pressure after their 
menopausal (Dubey et al., 2002). 
 
In Malaysia, the prevalence of hypertension is higher in other Bumiputras community 
(33.4%), follow by Indians (32.4%), Malays (31.1%) and lastly the Chinese 
community (30.8%) (Ministry of Health-Institute for Public Health, 2015). This might 
due to the different accessibility to the healthcare facilities, comprehensive prevention 
and control program that caused by geographical variation among different ethnicity 
(Wood & Euroaspire I and II Group, 2001). Other Bumiputras and Indians community 
mostly stay at the rural area; hence they may have limited accessibility to the 
healthcare services and regular healthcare screening, which might results in high 
prevalence among them (Abdul-Razak et al., 2016). Besides, various studies have been 
conducted globally on the racial and ethnic disparities in hypertension (see Hertz et al., 
2005, Hicken et al., 2014, Dong et al., 2016, Krishnadath et al., 2016, Nguyen-Huynh 
et al., 2016, Cai et al., 2017). Studies found that the highest prevalence of hypertension 
in adults is African descent, follow by Asian or Hispanic, and lastly is Caucasians 
descent (cite Krishnadath et al., 2016). 
 
1.1.5.2 Modifiable factors 
Lifestyle behaviours such as dietary, salt intake, physical activity and stress level may 
have contributed to the high prevalence of hypertension in Malaysia. The Dietary 
Approaches to Stop Hypertension (DASH) trial and various studies conducted 
internationally have provided substantial data that a diet that is high in fibres (fruits, 
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vegetables and nuts) and potassium, low saturated fat dairy products, focus on chicken 
and fish rather than red meat, limiting alcohol consumption would lower the blood 
pressure and it is particularly effective among individual who are low sodium intake 
(Appel et al., 1997, Stranges et al., 2004, Streppel et al., 2005, Bazzano et al., 2013). 
Studies reported that a reduction of 3-6 gram of salt per day would reduce the systolic 
blood pressure by estimated 3.6 to 5.6 mmHg and 1.9 to 3.2 mmHg diastolic blood 
pressures (Graudal, Galløe & Garred, 1998, He & MacGregor, 2003, Ha, 2014).  
 
Besides, physical activity is one of the most commonly recommendation to 
hypertensive patients as it is widely accessible, inexpensive and effective in reducing 
the blood pressure (Huai et al., 2013). Regularly engage with physical activity such as 
aerobic exercise and brisk walking for at least 30-40 minutes per day, 3-4 times a week 
would decrease the systolic and diastolic blood pressure by 1.56 to 5 mmHg / 0.74 to 
4 mmHg (Lakshminarayanan et al., 2012, Eckel et al., 2013). In addition, Yoga which 
included postures, breathing control and meditation had showed a significant effect on 
reducing the systolic and diastolic blood pressure, with an average decrease of 4.17 
mmHg and 3.62 mmHg respectively (Hagins et al., 2013, Manchanda & Madan, 2013). 
Physical activities and yoga would benefit the hypertensive as well as normotensive 
individual if they adhere to these activities for long term. 
 
Next, researches also demonstrated that hypertension patients who adhere to the 
healthy diet and lifestyle may reduce the systolic blood pressure from 2 to 14 mmHg 
(Appel et al., 2003, Dickinson et al., 2006, Eckel et al., 2013); However the effects of 
improvement in blood pressure is both patient and time dependent, hence, patients who 
are on strict diet and healthy lifestyle might have greater improvement compare to 
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those who are not. In additions, healthy diet and lifestyle not only assist in improving 
the blood pressure level but it also enhance the efficacy of the antihypertensive drugs 
and reduce the cardiovascular risk (Chobanian et al., 2003). Thus, in order to prevent 
hypertension and its related complications, healthy diet and lifestyle should be 
promoted among the patient with high blood pressure. 
 
On the other hand, medication adherence is well-known as an important factor that 
affect not only the blood pressure among hypertension patient but also to other chronic 
diseases such as diabetes and hyperlipidaemia (Fischer et al., 2010). Medication 
adherence is defined as the extent to which patients consume their medication as 
prescribed by the healthcare professional with respect to dosing and frequency (Ho, 
Bryson & Rumsfeld, 2009). Previous studies showed that there is a significant 
association between blood pressure control and medication adherence (Wu et al., 2010, 
Iloh et al., 2013, Jesus et al., 2016, Piercefield et al., 2016, Khayyat et al., 2017). Due 
to the asymptomatic nature of hypertension, individual with high blood pressure 
usually are unaware about their blood pressure level and do not seek for treatment on 
their health condition (Ming et al., 2011, Yi-Bing et al., 2013). Even if they are aware 
and get treated, they usually are not adhere to their antihypertensive medication and 
have uncontrolled blood pressure (Pereira et al., 2009). This was proven by the global 
statistics, where the rate of blood pressure control among hypertension patient remain 
unsatisfactory, only 10-20% of the patient have achieved the targeted blood pressure 
control (Pereira et al., 2009, Whelton, 2015). In Malaysia, a study conducted in Kuala 
Lumpur showed that among the hypertensive patients who are on treatment, only half 
of these patients had controlled blood pressure (Chia & Srinivas, 2009). Thus, there is 
a need to improve medication adherence among hypertension patient. And, among the 
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intervention to improve medication adherence, the effectiveness of CBP intervention 
was not reported in Southeast Asia setting especially in Malaysia, whereby the 
prevalence of hypertension is high and adherence rate is low (Ministry of Health-
Institute for Public Health, 2015). 
 
1.2 Overview of thesis 
In this thesis, Chapter Two reviews the literature related to the study with the definition 
of terminologies, types of medication non-adherence, followed by a brief discussion 
of the clinical and economic impotencies of medication adherence. This chapter 
continue with an overview of medication adherence and various measurement tools 
used to evaluate patients adherence. The pro and cons of each adherence measurements 
was discussed in depth in this chapter. This chapter is completed with a review of 
literature relevant to the study; focus on the effectiveness of CBP towards medication 
adherence, clinical and economic outcomes regardless of the disease, medications, 
study setting and population.    
 
Methodologies use in this study were discussed in Chapter Three. A detail discussion 
of the methodology used for both qualitative and quantitative studies which included 
the reasons of selecting a particular method, study setting and statistical analyses is 
presented in this chapter. In addition, results interpretation of the selected adherence 
measurements and threshold for dichotomous adherence and blood pressure outcomes 
are discussed in this chapter. 
 
Chapter Four will illustrate the findings of this study. The findings from focus group 
discussion conducted with hypertensive patients about their perception, opinion and 
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knowledge on medication packaging and CBP are discussed in this chapter. The 
validation results on selected adherence measurements and blood pressure are also 
presented in this chapter. Besides, this chapter reported the findings from randomized 
controlled trial which included the patient demographic characteristic, pre and post 
intervention assessment on adherence and blood pressure, as well as the treatment cost 
associated with study patients. 
   
Chapter Five is a discussion chapter for this thesis. Patients’ perception on name, 
appearance and labelling are discussed in this chapter. This chapter also included the 
reasons on how medication packaging and CBP medication affect patient adherence, 
the benefits of CBP and the factors associated with the selected adherence 
measurements. Last but not least, the potential barriers of medication adherence and 
the advantages of CBP against pillbox organizer can also be found in this chapter. 
 
Chapter Six is the final chapter for this thesis. It summarized the overall findings for 
this study and draws a conclusion for this thesis. Besides, the limitations in this study 










CHAPTER 2 LITERATURE REVIEW 
2.1 Medication adherence 
This chapter provide an overview on the topics related to this study and a general 
review of the literature. 
 
2.1.1 Definition of medication adherence 
According to the former American surgeon Everett Koop, “Drugs don’t work in 
patients who don’t take them” (Osterberg & Blaschke, 2005). This phrase was then 
modified by Blaschke et al in 2012 to “drugs work erratically in patients who take 
them erratically”(Blaschke et al., 2012). In short, a medication effectiveness in 
treating a disease is depends on patient’s behaviour in following the therapeutic 
regimen. 
 
Various terms (e.g. compliance, adherence, persistence, and concordance) are being 
used to describe patient’s behaviour in taking their medications prescribed by the 
healthcare professional. The most commonly-used terms are compliance and 
adherence. Even though these terms have been used interchangeably in explaining the 
patient’s behaviour in continuing to take their prescribed medication, but their 
connotations are slightly different between these two terms. Compliance is a traditional 
term, which is defined as the extent to which patients obey the recommendation or 
instructions of healthcare provider (Lutfey & Wishner, 1999, Horne et al., 2005). 
Healthcare provider would layout the therapeutic goal and recommendation to achieve 
the goal, patients would then endure to the provider’s authority and obey the order 




On the other hand, adherence is the extent to which patient followed the treatment 
regimen voluntarily as the healthcare provider have collaborate with the patients to 
improve patient’s health by combining the provider’s professional medical opinions 
with patient’s lifestyle and preferences of care (Brown & Bussell, 2011). The term 
adherence also means that patients are more proactive and willing to have open 
discussion with the healthcare provider on their health related decision; and this term 
also focus on building a good collaboration between healthcare provider and patients 
in order to achieve the therapeutic goal (Swaminath, 2007). Thus, both healthcare 
provider and patients have the equal responsibilities on the outcomes of a treatment 
plan. Besides, adherence has been defined by World Health Organization as “the 
extent to which a person’s behaviour- taking medication, following a diet, and/or 
executing lifestyle changes corresponds with agreed recommendation from a 
healthcare provider” (Sabaté, 2003).  
 
In the current medical terminology, majority of the authors support and prefer to use 
the term adherence compared to compliance (Horne et al., 2005, Aronson, 2007, 
Chakrabarti, 2014). This might due to the reason that adherence is able to reflect the 
collaboration between patient and the healthcare provider in decision making related 
to their treatment plan (Osterberg & Blaschke, 2005). Whereas, the term compliance 
reflect the passive way where the healthcare provider decided a correct treatment plan 
for the patient, and patient has to comply or obey with the treatment plan regardless of 





As compared to compliance and adherence, persistence and concordance are less 
commonly used by the healthcare provider or researchers. Concordance refers to an 
agreement between the provider and patient on the purpose of a treatment plan and the 
treatment regimen that the patient will consume (Aronson, 2007). Concordance does 
not refer to a patient’s medicine-taking behaviour but emphasis on the nature of 
interaction between healthcare provider and patients on setting out the goals for 
therapy and not arbitrarily enforcing a treatment regimen (Bell et al., 2007, Fraser, 
2010). This term may sometimes be used incorrectly as an interchangeably words for 
“adherence” and “compliance” (Hugtenburg et al., 2013). Persistence refers to “the 
duration of time from the initiation to discontinuation of the therapy”(Cramer et al., 
2008). Although conceptually persistence and adherence are similar, but persistence is 
defined as how long patient will continuously stay with their treatment, and adherence 
refer to how well patient follow the treatment regimen as prescribed by the provider 
(Hugtenburg et al., 2013). 
 
Medication adherence is usually being described as low or poor versus high or good 
adherence towards treatment regimen among patient. While, non-adherence refers to 
patient’s resistance or refusal against properly adhere to the treatment regimen or 
therapy prescribed by the provider. In general, patient who suffer from acute disease 
would have high adherence rate compared to patients with chronic diseases (Sabaté, 
2003). Patient adherence toward long term medication such as hypertension and 
diabetes is generally low, and usually drop dramatically after the first six months of 
the treatment (Osterberg & Blaschke, 2005). Non-adherence to medication prescribed 




2.1.2 Intentional and unintentional non-adherence 
There are many reasons why patient is non-adherence to their prescribed medication. 
Generally these reasons fall into two overlapping categories that is intentional and 
unintentional adherence (Lowry et al., 2005, Gadkari & McHorney, 2012, Molloy et 
al., 2014, Mukhtar, Weinman & Jackson, 2014).  
 
Intentional non-adherence refer to non-adherence that is purposively and mainly 
associated with patient motivation. Patient with intentional non-adherence may have 
gone through a careful consideration to evaluate the pros and cons of a treatment before 
decided not to follow the treatment regimen and recommendation (Lowry et al., 2005, 
Clifford, Barber & Horne, 2008). Patient beliefs about medicine and disease, culture, 
and religion played an important role during this consideration or decision making 
process either to adhere or non-adherent to the regimen (Iihara et al., 2004, Goodfellow 
et al., 2013, Egenasi, Steinberg & Raubenheimer, 2015, Kumar et al., 2016). 
 
Besides, patient might struggle during this consideration process as they might get 
information from medicine leaflet regarding to the side effect or other adverse effect 
of their medicine,  and they might get confuse, lack of confident, or become sceptical 
about their treatment (Hugtenburg et al., 2013). In addition, certain treatment plan such 
as antiretroviral and mental therapy might stigmatize or remind the patient about their 
illness (Sirey et al., 2001, Sabaté, 2003). These factors might also influence patient’s 





Unintentional non-adherence refers to non-adherence that is mainly driven by 
limitation in capacity and resources to continue taking medications, as well as 
individual constraints such as memory and dexterity  (Horne et al., 2005, Clifford et 
al., 2008). This is usually an unplanned behaviour and less likely to be associated with 
belief, culture, religious and side effect of the medication. Patient behaviour such as 
forgetfulness, missing dosages, losing medical attention, skipping appointments, 
inability to pay for treatment, difficulties in understanding the instructions and 
overloaded with medical information at once might lead to unintentional non-
adherence in patients (Lehane & McCarthy, 2007, Bastakoti et al., 2013, Feldman et 
al., 2017).  
 
Next, complexity of the medication regimen and complicated schedule for patients to 
take their medication might also result in unintentional non-adherence. For instance, 
drug-drug interactions such as tetracyclines or bisphosphonates should be taken 
separately from painkiller, calcium, aluminium, magnesium or iron salts. Some 
painkiller such as aspirin and ibuprofen can cause irritation at oesophagus if the patient 
ingest it with bisphosphonates. Where as, calcium would interfere with the absorption 
or lower the bioavailability of the bisphosphonates if it were taken together with 
bisphosphonates (Cascorbi, 2012). Thus, bisphosphonates should be consumed 30 
minutes before meal and taken separately from other medicines. Besides, patient are 
required to maintain on upright posture for 30-60 minutes after taken bisphosphonate 
with a full glass of water (Rizzoli et al., 2011). Due to this complex and complication 
medication taking schedule, patient might hardly adhere to their medicines, as they 




2.1.3 Burden of medication adherence in hypertension 
Medication non-adherence is common among patients. The prevalence of adherence 
to chronic medication regimens is dramatically low as compared to acute diseases 
(Sabaté, 2003). This situation was clearly reflected in hypertensive patients, whereby 
approximately 43% to 80% of the hypertensive patients fail to adhere to their 
prescribed medications (Sabaté, 2003, Van Wijk et al., 2005, Burke et al., 2006, 
Kulkarni et al., 2006, Elliott, 2008, Klootwyk & Sanoski, 2011, Krousel-Wood et al., 
2011, Barreto et al., 2015, Abegaz et al., 2017). The higher percentage of non-
adherence rate was found among African populations such as Ivory Coast (87.5%), 
Togo (83.7%), Congo (78.8%) and Tunisia (63.4%); followed by Asians (43.5%), 
Europeans (36.6%) and Americans (36.6%) (Konin et al., 2007, Ghozzi et al., 2010, 
Abegaz et al., 2017). The discrepancies of non-adherence rate may be due to 
differences in the population studied, ethnic or cultural differences, sample size, as 
well as difference in the adherence measurement methods in the studies. 
 
Besides, approximately 16% to 50% of the patients who are newly diagnosed with 
hypertension have stopped their medication within the first 12 months after their first 
antihypertensive regimens (Jones et al., 1995, Flack, Novikov & Ferrario, 1996, 
Vrijens et al., 2008, Azizi et al., 2016). In addition, a study conducted among 4783 
hypertensive patients found that on each day, 10% of these patients who are still 
engaged with the antihypertensive regimens omitted their scheduled doses of  
medication (Vrijens et al., 2008). According to Bailey et al, this small deviations in 
medication adherence can be clinically important, as increasing patient adherence to 
antihypertensive medication by just one pill per week for daily regimen could reduce 
the risk of stroke by 8-9% and death by 7% (Bailey et al., 2010).  
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Non-adherence to antihypertensive medication is one of the important factor that lead 
to uncontrolled blood pressure among the patients (Sabaté, 2003, Bramley et al., 2006). 
Among patients who are non-adherence to their antihypertensive medication, 
approximately 62.4% to 83.7% of them were uncontrolled blood pressure patients (de 
Oliveira-Filho et al., 2014a, Abegaz et al., 2017). A recent meta-analysis suggested 
that an increase of 10 mmHg in systolic blood pressure in hypertensive patients with 
systolic blood pressure above 130 mmHg, would increases the risk of major 
cardiovascular disease events by 20%, coronary heart diseases by 17%, 27% of stroke, 
28% of heart failure, and all-cause mortality by 13% (Ettehad et al., 2016). Thus, 
failure to achieve the targeted blood pressure level would increases the hazard of 
myocardial infarction, stroke, cardiovascular mortality and hospitalization (Lewington 
et al., 2002, Ho et al., 2008, Kettani et al., 2009, Wong et al., 2013). 
 
Next, poor medication adherence was also associated with greater risk of mortality and 
higher hospitalization rates among patients (Pesa et al., 2012, Bitton et al., 2013, Shin 
et al., 2013, Kim et al., 2016b). Hypertensive patients who are non-adherent to their 
medication have 5.4 times higher risk of premature death compared to patients who 
adhere to their regimens (Gwadry-Sridhar et al., 2009). In addition, a cohort study 
conducted among 59,647 hypertensive patients in Canada reported that patients who 
are low adherence to their treatment regimens was 17% higher risk of hospitalization 
(Dragomir et al., 2010). Indirectly, non-adherence to treatment regimens would 
increase the healthcare costs due to disease progression, hospitalization and 




In United States, it is estimated that a total of USD 105 billion is wasted annually due 
to medication non-adherence. Among the chronic diseases, hypertension is one of the 
top three chronic diseases with the highest avoidable cost, which amount up to 18.6 
billion annually. Approximately 69% of the avoidable costs is spent on the avoidable 
hospitalization cost (IMS Institute for Healthcare Informatics, 2013). While, other 
direct medical costs such as ad hoc service utilization at emergency department, 
comorbidity conditions, and addition diagnostic test resulted from the progression of 
the disease; these costs can be avoided if the patient adhere to their treatment regimens 
and control the disease at the primary stage (Iugo & McGuire, 2014). Besides, studies 
showed that if hypertensive patient adhere to their treatment regimens, it would save 
up to an averagely USD 3,908 per patients annually and reduced the total 
hospitalization cost by more than 25 million per year (Dragomir et al., 2010, Roebuck 
et al., 2011). 
 
In summary, the global prevalence of medication non-adherence is high among chronic 
diseases patients. Non-adherence to antihypertensive treatment regimen is associated 
with the progression of the disease, poor health-related quality of life, increased 
healthcare utilisation and costs. Future development of measures to improve 
medication adherence is urgently needed to fully address these issue.   
 
2.2 Measurement of medication adherence 
Assessing medication adherence is a big challenge yet important component for both 
researchers and clinicians in the process of developing intervention to improve 
adherence among the patients. Accurate evaluation of patient adherence would provide 
a clear picture of the risk factors, consequences and strategies to improve patient 
